$14.98
+0.32 (+2.18%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PMN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 with posted results
Held by 1 tracked-famous manager (MILLENNIUM MANAGEMENT LLC) · FINRA short interest 1.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)NCT06750432Safety and tolerability of PMN310 following repeat intravenous infusions of PMN310Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: PMN310, Placebo | Alzheimer Disease, Early Onset | 144 | Dec 2026 | ≤ 134 d | 2026-07-13 |
| A Phase 1a Study of PMN310 In Healthy VolunteersNCT06105528results2025-07-25Incidence of Treatment Emergent Adverse EventsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: PMN310, Placebo | Healthy Participants | 40 | 2024-07-31actual | — | 2025-07-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19